Botox Approved for Neurogenic Detrusor Overactivity in Pediatric Patients
The approval is supported by data from a phase 3 study that assessed the efficacy and safety of Botox in patients aged 5 to 17 years with urinary incontinence due to NDO and using clean intermittent catheterization.